Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Idalia Liboy
Observed name:
I. Liboy
Institution:
Auxilio Mutuo Hospital
Observed institution:
Auxilio Mutuo Hospital
OpenAlex ID:
A5026190976
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
2006
·
F. Cabanillas
, I. Liboy
, et al.
·
Annals of Oncology
·
85
PDF
A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin’s lymphoma (NHL): Gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim
2006
·
F. Cabanillas
, I. Liboy
, et al.
·
Journal of Clinical Oncology
·
6
Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19
2021
·
Fernando Cabanillas
, Javier Morales
, et al.
·
medRxiv
·
5
PDF
Home-based management of COVID-19 by identification of low-risk features
2021
·
Fernando Cabanillas
, Javier Morales
, et al.
·
medRxiv
·
3
PDF
GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin’s lymphoma (NHL)
2008
·
F. Cabanillas
, I. Liboy
, et al.
·
Journal of Clinical Oncology
·
3
Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
2017
·
Fernando Cabanillas
, Idalia Liboy
, et al.
·
Journal of Clinical Oncology
·
2
The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)
2008
·
Fernando Cabanillas
, Jorge Toro
, et al.
·
Blood
·
2
A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev)
2019
·
Fernando Cabanillas
, Noridza Rivera
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Results of a novel neoadjuvant chemotherapy (NAC) regimen for breast cancer.
2013
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
·
1
An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas.
2012
·
Robert M. Crescentini
, Kendra Lynn Sweet
, et al.
·
Journal of Clinical Oncology
·
1
Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfi lgrastim as support
2012
·
Fernando Cabanillas
, Maribel Cotto
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
1
Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease.
2011
·
M. Cotto
, F. Cabanillas
, et al.
·
Journal of Clinical Oncology
·
1
A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas
2010
·
Jennifer L. Cultrera
, Jijun Liu
, et al.
·
Blood
·
1
Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL).
2006
·
Fernando Cabanillas
, Jorge Toro
, et al.
·
Blood
·
1
Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).
2010
·
Maribel Cotto
, Fernando Cabanillas
, et al.
·
Blood
Dose-seeking study of the combination of GM-CSF with pegfilgrastim plus CHOP-rituximab in patients with aggressive non- Hodgkin lymphoma (NHL)
2007
·
F. Cabanillas
, O. Pavia
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
16
Citation count:
113
H-index:
3
I10-index:
1
Year
Topic
Type